MItral Regurgitation Risk Assessment and CLinical ModElling

Last updated: March 13, 2025
Sponsor: Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mitral Valve Regurgitation

Treatment

N/A

Clinical Study ID

NCT06876883
MIRACLE study
  • Ages > 18
  • All Genders

Study Summary

Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation.

MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization.

  • Aged over 18 yrs.

Exclusion

Exclusion Criteria:

  • Patients unable to provide written consent.

Study Design

Total Participants: 2000
Study Start date:
June 15, 2016
Estimated Completion Date:
June 15, 2030

Connect with a study center

  • The First Affiliated Hospital of Sun Yat-sen Univerity

    Guangzhou, Guangdong 510000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.